Sponsor or institution

Clinical trials and research at Multitude Therapeutics Inc.

• 8Clinical trials
• 4Countries

Newest trials

All recruiting trials (8)

• AMT-116 vs doctor’s choice in advanced non-squamous NSCLC that is EGFR-wild and progressed after platinum and PD-1/PD-L1 therapy

  This study tests AMT-116 in adults with advanced non-squamous NSCLC that is EGFR-wild, comparing different doses to doctor’s choice after prior platinum and immunotherapy.

  Recruiting Phase 2/3 Multitude Therapeutics Inc. · Port Saint Lucie, Florida and 6 other locations · NCT07718737

• AMT-116 with AK112 in advanced NSCLC

  This study tests whether AMT-116 plus Ivonescimab (AK112) is safe and helpful for adults with advanced non-small cell lung cancer who can’t be cured with surgery or standard treatment.

  Recruiting Phase 1/2 Multitude Therapeutics Inc. · Guangzhou, Guangdong and 1 other locations · NCT07590531

• AMT-676 combinations for advanced colorectal cancer

  This study tests AMT-676 together with standard chemotherapy and targeted therapies to see if it’s safe and effective for people with unresectable advanced colorectal cancer.

  Recruiting at 8 sites Phase 2 Multitude Therapeutics Inc. · Fuzhou, Fujian and 18 other locations · NCT07474727

• Evaluating AMT-116 for advanced solid tumors

  This study is testing a new treatment called AMT-116 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 6 sites Phase 1/2 Multitude Therapeutics Inc. · Fuzhou, Fujian and 6 other locations · NCT06782334

• Evaluating AMT-676 for advanced solid tumors

  This study is testing a new treatment called AMT-676 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 5 sites Early Phase 1 Multitude Therapeutics Inc. · Huntersville, North Carolina and 12 other locations · NCT06400485

• AMT-253 treatment for advanced solid tumors

  This study is testing a new treatment called AMT-253 to see if it can help people with advanced melanoma and other solid tumors who have run out of other treatment options.

  Recruiting Phase 1/2 Multitude Therapeutics Inc. · Beijing, Beijing Municipality · NCT06209580

• Evaluating AMT-253 for advanced solid tumors

  This study is testing a new treatment called AMT-253 to see if it is safe and effective for people with advanced solid tumors who have run out of other treatment options.

  Recruiting at 7 sites Phase 1 Multitude Therapeutics Inc. · Sydney, New South Wales and 6 other locations · NCT05906862

• Evaluating AMT-116 for patients with advanced solid tumors

  This study is testing a new treatment called AMT-116 to see if it can safely help people with advanced solid tumors that haven’t responded to other therapies.

  Recruiting at 8 sites Phase 1 Multitude Therapeutics Inc. · Denver, Colorado and 9 other locations · NCT05725291

Quick answers

How many clinical trials run by Multitude Therapeutics Inc. are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in China (5 trials), Australia (4 trials), American Samoa (2 trials), United States (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 3, Phase 1: 2, Phase 2: 1, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →